A number of large studies and reviews of isoniazid monotherapy have concluded that the incidence of serious hepatitis (ALT >5 ULN) is between 0.1 and 0.56%; a figure taken as the correct answer to this question [6–8]. This evidence concerns the gene GPT and hepatitis A virus infection.